Online Only Articles

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Vol. 101 No. 8 (2016): August, 2016 https://doi.org/10.3324/haematol.2015.139089